Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
163 hedge funds and large institutions have $516M invested in Eagle Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 72 reducing their positions, and 11 closing their positions.
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
2% more funds holding
Funds holding: 160 → 163 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $555M → $516M (-$39.3M)
31% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$13.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.5M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$5.64M |
| 4 |
Morgan Stanley
New York
|
+$2.99M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$6.4M |
| 2 |
AC
Armistice Capital
New York
|
-$3.4M |
| 3 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
-$3.22M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.17M |
| 5 |
Janus Henderson Group
London,
|
-$2.21M |
EGRX Hedge Fund Activity: Q2 2022 in Review
163 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2022, worth a combined $516M — down 7.1% from $555M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new EGRX positions and 11 closed out — a net gain of 8 holders — while 50 added to existing stakes and 72 trimmed.
The largest buyer was Millennium Management, adding an estimated $13.9M. The largest seller was Man Group, exiting entirely with an estimated $6.4M sold.
- 163 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2022, up from 160 in Q1 2022.
- Funds reported $516M of Eagle Pharmaceuticals, Inc. stock for Q2 2022, down 7.1% quarter-over-quarter.
- 19 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2022 and 11 closed out, a net change of +8 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2022 was Millennium Management, an estimated $13.9M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2022 was Man Group, an estimated $6.4M sold.
Based on aggregated 13F filings for Q2 2022.